With Aduhelm in turmoil, Biogen eyes a list of potential acquisitions


Biogen, desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment Aduhelm, has a shopping list of potential acquisitions, STAT has learned. And the company’s risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive.

The company, whose stock price is down nearly 50% since Aduhelm’s June approval, is working with Goldman Sachs to find potential buyout targets, according to a person familiar with the companies’ relationships who would share internal discussions only on the condition of anonymity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

Scroll to Top